




[12] Patent

[11] Patent No.: GC 0000318	Number of the Decision to Grant the Patent: 5/1636
[45] Date of Publishing the Grant of the Patent: 01/11/2006 6/2006	Date of the Decision to Grant the Patent: 19/12/2005
[21] Application No.: GCC/P/2002/1833 [22] Filing Date: 28/01/2002 [30] Priority: [31] Priority No. [32] Priority date [33] State 01101947.8 29/01/2001 EP [72] Inventors: 1- Alexander Alanine, 2- Bernd Buettelmann, 3- Marie Paule Heitz, 4- Georg Jaeschke, 5- Emmanuel Pinard, 6- Rene Wyler [73] Owner: F. Hoffmann – La Roche AG, 124 Grenzacherstrasse, CH-4070 Basle, Switzerland [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. ⁷ : C07D 233/54, 233/61, 233/84 [56] Cited Documents: - EP 1070708 A (HOFFMANN LA ROCHE) 24 January 2001 - WO 9954314 A (BECHTEL WOLF DIETRICH; BOEHRINGER INGELHEIM PHARMA (DE); PALLUK (RA)) 28 October 1999

[54] IMIDAZOLE DERIVATIVES

[57] Abstract: The invention related to compounds of the general formula:



where in the substituents are defined in claim 1. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are therefore suitable in the control or treatment of diseases, related to this receptor

No. of claims: 27